Marburg, Ebola Sudan Vaccines Might Get Share of COVAX Surplus 04/07/2023 Megha Kaveri Some of the $2.6 billion that remains in a COVID-19 vaccine delivery scheme, COVAX, could be redirected into investment into investigational vaccine candidates for Marburg Virus Disease (MVD) and Ebola Sudan strain virus, as well as over half a dozen other vaccine programmes that were suspended due to the pandemic or delays in product development, […] Continue reading -> Shock Withdrawal of Gavi CEO-Designate as Board Ponders COVAX Funds Surplus 26/06/2023 Kerry Cullinan Six weeks before its new CEO was due to assume office, global vaccine alliance Gavi has announced that Dr Muhammad Pate is no longer available for the position. The appointment of Pate, a former Nigerian health minister, was announced in February following a meeting of the Gavi board. He was to replace current CEO Dr […] Continue reading -> COVAX Vaccines Helped Avert 2.7 Million COVID Deaths – But Could Have Saved More With Stable Regional Supplies 02/05/2023 Kerry Cullinan By the end of 2022, COVID-19 vaccines delivered by the global vaccine access initiative, COVAX, helped to avert 2.7 million deaths across 92 lower-income countries, according a new report based on modelling by researchers from Imperial College London. COVAX’s biggest success was in low-income countries, where its vaccines were responsible for three-quarters of all deaths […] Continue reading -> Trials of Three Ebola Candidate Vaccines Set for Uganda; India’s Covaxin Vaccine Still Suspended by WHO 16/11/2022 Megha Kaveri Clinical trials on three Ebola vaccine candidates for the Sudan strain of the virus are due to start soon in Uganda, according to the World Health Organization (WHO). “I’m pleased to announce that a WHO committee of external experts has evaluated three candidate vaccines and agreed that all three should be included in the planned […] Continue reading -> COVAX, the Global COVID-19 Vaccine Platform, was ‘Too Ambitious’ 14/10/2022 Kerry Cullinan Midway through last year, the head of the Africa Vaccine Acquisition Task Team, Strive Masiyiwa, angrily accused the global COVID-19 vaccine acquisition platform, COVAX, of misleading African countries about its ability to procure vaccines for them. Masiyiwa’s bitter remarks came after months of Africans watching Europeans and North Americans being vaccinated against COVID-19 while no […] Continue reading -> COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Shock Withdrawal of Gavi CEO-Designate as Board Ponders COVAX Funds Surplus 26/06/2023 Kerry Cullinan Six weeks before its new CEO was due to assume office, global vaccine alliance Gavi has announced that Dr Muhammad Pate is no longer available for the position. The appointment of Pate, a former Nigerian health minister, was announced in February following a meeting of the Gavi board. He was to replace current CEO Dr […] Continue reading -> COVAX Vaccines Helped Avert 2.7 Million COVID Deaths – But Could Have Saved More With Stable Regional Supplies 02/05/2023 Kerry Cullinan By the end of 2022, COVID-19 vaccines delivered by the global vaccine access initiative, COVAX, helped to avert 2.7 million deaths across 92 lower-income countries, according a new report based on modelling by researchers from Imperial College London. COVAX’s biggest success was in low-income countries, where its vaccines were responsible for three-quarters of all deaths […] Continue reading -> Trials of Three Ebola Candidate Vaccines Set for Uganda; India’s Covaxin Vaccine Still Suspended by WHO 16/11/2022 Megha Kaveri Clinical trials on three Ebola vaccine candidates for the Sudan strain of the virus are due to start soon in Uganda, according to the World Health Organization (WHO). “I’m pleased to announce that a WHO committee of external experts has evaluated three candidate vaccines and agreed that all three should be included in the planned […] Continue reading -> COVAX, the Global COVID-19 Vaccine Platform, was ‘Too Ambitious’ 14/10/2022 Kerry Cullinan Midway through last year, the head of the Africa Vaccine Acquisition Task Team, Strive Masiyiwa, angrily accused the global COVID-19 vaccine acquisition platform, COVAX, of misleading African countries about its ability to procure vaccines for them. Masiyiwa’s bitter remarks came after months of Africans watching Europeans and North Americans being vaccinated against COVID-19 while no […] Continue reading -> COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVAX Vaccines Helped Avert 2.7 Million COVID Deaths – But Could Have Saved More With Stable Regional Supplies 02/05/2023 Kerry Cullinan By the end of 2022, COVID-19 vaccines delivered by the global vaccine access initiative, COVAX, helped to avert 2.7 million deaths across 92 lower-income countries, according a new report based on modelling by researchers from Imperial College London. COVAX’s biggest success was in low-income countries, where its vaccines were responsible for three-quarters of all deaths […] Continue reading -> Trials of Three Ebola Candidate Vaccines Set for Uganda; India’s Covaxin Vaccine Still Suspended by WHO 16/11/2022 Megha Kaveri Clinical trials on three Ebola vaccine candidates for the Sudan strain of the virus are due to start soon in Uganda, according to the World Health Organization (WHO). “I’m pleased to announce that a WHO committee of external experts has evaluated three candidate vaccines and agreed that all three should be included in the planned […] Continue reading -> COVAX, the Global COVID-19 Vaccine Platform, was ‘Too Ambitious’ 14/10/2022 Kerry Cullinan Midway through last year, the head of the Africa Vaccine Acquisition Task Team, Strive Masiyiwa, angrily accused the global COVID-19 vaccine acquisition platform, COVAX, of misleading African countries about its ability to procure vaccines for them. Masiyiwa’s bitter remarks came after months of Africans watching Europeans and North Americans being vaccinated against COVID-19 while no […] Continue reading -> COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Trials of Three Ebola Candidate Vaccines Set for Uganda; India’s Covaxin Vaccine Still Suspended by WHO 16/11/2022 Megha Kaveri Clinical trials on three Ebola vaccine candidates for the Sudan strain of the virus are due to start soon in Uganda, according to the World Health Organization (WHO). “I’m pleased to announce that a WHO committee of external experts has evaluated three candidate vaccines and agreed that all three should be included in the planned […] Continue reading -> COVAX, the Global COVID-19 Vaccine Platform, was ‘Too Ambitious’ 14/10/2022 Kerry Cullinan Midway through last year, the head of the Africa Vaccine Acquisition Task Team, Strive Masiyiwa, angrily accused the global COVID-19 vaccine acquisition platform, COVAX, of misleading African countries about its ability to procure vaccines for them. Masiyiwa’s bitter remarks came after months of Africans watching Europeans and North Americans being vaccinated against COVID-19 while no […] Continue reading -> COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVAX, the Global COVID-19 Vaccine Platform, was ‘Too Ambitious’ 14/10/2022 Kerry Cullinan Midway through last year, the head of the Africa Vaccine Acquisition Task Team, Strive Masiyiwa, angrily accused the global COVID-19 vaccine acquisition platform, COVAX, of misleading African countries about its ability to procure vaccines for them. Masiyiwa’s bitter remarks came after months of Africans watching Europeans and North Americans being vaccinated against COVID-19 while no […] Continue reading -> COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVAX Tackles ‘Last Mile’ of Getting Vaccines into Arms 06/05/2022 Kerry Cullinan Now that COVAX has enough stock of COVID-19 vaccines, its focus is on vaccination uptake – including encouraging countries to combine campaigns against measles and polio with COVID-19, and even helping with “campaign-style” vaccination drives. This emerged at a media briefing on vaccine delivery called by the Access to COVID-19 Tools (ACT) Accelerator, of which […] Continue reading -> China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
China, not COVAX, Led Vaccine Exports to the World’s Middle Income Countries in 2021 10/02/2022 Xiaoyi Wang While China’s rigorous management of virus risks at home has received considerable attention, particularly as it hosts the 2022 winter Olympics, it’s massive vaccine effort abroad has been underreported. In fact, as of end 2021, Beijing had supplied more COVID vaccines to low- and middle-income countries than the WHO co-sponsored COVAX facility. Against the constant […] Continue reading -> COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVAX Update: Enough Vaccines but Big Disparities in Uptake – Exacerbating Risks of New Variants 24/01/2022 Paul Adepoju With the delivery of its one billionth dose last week, COVAX, the WHO co-sponsored vaccine facility, has established itself as the main pillar of vaccine supplies to the world’s 92 poorest economies – providing 82% of the vaccines those nations have received so far. But even as vaccine supplies now ease up, huge disparities persist […] Continue reading -> COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVAX Delivers One Billionth COVID-19 Vaccine Dose – But 41% of World Remains Unvaccinated 17/01/2022 Kerry Cullinan Rwanda became the recipient of the one-billionth COVID-19 vaccine delivered by COVAX, the global platform set up to ensure equitable access to the vaccines,announced last Friday. After numerous supply problems – most seriously when its key supplier, the Serum Insitute of India, was banned from exporting its vaccines by the Indian government – COVAX was […] Continue reading -> India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
India’s Covaxin Vaccine Shows 77.8% Efficacy in Interim Phase 3 Results 11/11/2021 Raisa Santos Following World Health Organization approval last week, interim data from a phase 3 trial of BBV152, a COVID-19 vaccine developed in India, reports 77.8% efficacy against symptomatic COVID-19. The study, published in The Lancet, indicated that BBV152 induced a robust antibody response, with the majority of adverse events, including headache, fatigue, fever, and pain at […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy